Voyager Therapeutics, Inc.

NasdaqGS:VYGR Stock Report

Market Cap: US$316.3m

Voyager Therapeutics Management

Management criteria checks 3/4

Voyager Therapeutics' CEO is Al Sandrock, appointed in Mar 2022, has a tenure of 2.75 years. total yearly compensation is $3.17M, comprised of 19.7% salary and 80.3% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $363.85K. The average tenure of the management team and the board of directors is 2.3 years and 4.9 years respectively.

Key information

Al Sandrock

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage19.7%
CEO tenure2.8yrs
CEO ownership0.1%
Management average tenure2.3yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral

Nov 18

Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified

Oct 17
Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified

Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround

Aug 26

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 09
Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Aug 08
Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Jun 05

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Mar 15
There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Mar 08

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Mar 04
What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Jan 04
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target

Oct 04

Voyager Therapeutics hires new finance chief

Sep 07

Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02

Aug 04

Looking Back In On Voyager Therapeutics

Jun 08

Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

May 12
Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

Voyager Does A Reboot After First Generation Failures

Mar 25

CEO Compensation Analysis

How has Al Sandrock's remuneration changed compared to Voyager Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$26m

Jun 30 2024n/an/a

US$9m

Mar 31 2024n/an/a

-US$3m

Dec 31 2023US$3mUS$624k

US$132m

Sep 30 2023n/an/a

US$52m

Jun 30 2023n/an/a

US$96m

Mar 31 2023n/an/a

US$99m

Dec 31 2022US$7mUS$525k

-US$46m

Compensation vs Market: Al's total compensation ($USD3.17M) is above average for companies of similar size in the US market ($USD2.11M).

Compensation vs Earnings: Al's compensation has been consistent with company performance over the past year.

CEO

Al Sandrock (66 yo)

2.8yrs

Tenure

US$3,172,433

Compensation

Dr. Alfred W. Sandrock Jr., also known as Al, M.D., Ph D., served as Director at Verge Analytics, Inc. since February 2022. He served as Member of Scientific Advisory Board at Camp4 Therapeutics Corporatio...

Leadership Team

NamePositionTenureCompensationOwnership
Alfred Sandrock
President2.8yrsUS$3.17m0.12%
$ 363.9k
Robin Swartz
Chief Business Officer & COOno dataUS$1.38m0.062%
$ 195.0k
Jacquelyn Sandell
Chief Legal Officer1.4yrsUS$1.91m0.026%
$ 83.0k
Krystof Bankiewicz
Founderno datano datano data
Guangping Gao
Founder & Member of Scientific Advisory Boardno datano datano data
Mark Kay
Founderno datano datano data
Phillip Zamore
Founder & Member of Scientific Advisory Boardno datano datano data
Nathan Jorgensen
Chief Financial Officerless than a yearno datano data
Todd Carter
Chief Scientific Officer2.3yrsno data0.16%
$ 507.3k
Michelle Smith
Chief Human Resources Officer4.3yrsno datano data
Trista Morrison
Chief Corporate Affairs Officer & Chief of Staff to the CEO2.9yrsno datano data
Toby Ferguson
Chief Medical Officerless than a yearno datano data

2.3yrs

Average Tenure

53.5yo

Average Age

Experienced Management: VYGR's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alfred Sandrock
President2.8yrsUS$3.17m0.12%
$ 363.9k
Guangping Gao
Founder & Member of Scientific Advisory Boardno datano datano data
Phillip Zamore
Founder & Member of Scientific Advisory Boardno datano datano data
Dinah Sah
Consultant & Member of Scientific Advisory Board5.5yrsUS$1.81mno data
James Arthur Geraghty
Independent Director10.9yrsUS$263.78k0.10%
$ 316.1k
Glenn Pierce
Independent Director7.9yrsUS$248.78k0.040%
$ 126.2k
Steven Hyman
Independent Director9.3yrsUS$255.78k0%
$ 0
Michael Higgins
Independent Chairman of the Board9.4yrsUS$281.28k0.057%
$ 181.3k
Catherine Mackey
Independent Director2.4yrsUS$250.78k0%
$ 0
Jude Onyia
Director1.8yrsUS$452.32k0.0053%
$ 16.9k
Grace Colon
Independent Director1.9yrsUS$432.23k0%
$ 0
Nancy Vitale
Independent Director4.3yrsUS$255.28k0%
$ 0

4.9yrs

Average Tenure

64.5yo

Average Age

Experienced Board: VYGR's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 22:46
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Voyager Therapeutics, Inc. is covered by 25 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Jack AllenBaird
Aydin HuseynovBenchmark Company